Claritas Pharmaceuticals Inc
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Market Cap & Net Worth: Claritas Pharmaceuticals Inc (CLAZF)
Claritas Pharmaceuticals Inc (PINK:CLAZF) has a market capitalization of $3.66K ($3.66K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #46730 globally and #14528 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Claritas Pharmaceuticals Inc's stock price $0.00 by its total outstanding shares 36586089 (36.59 Million).
Claritas Pharmaceuticals Inc Market Cap History: 2015 to 2025
Claritas Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $106.10K to $3.66K (-30.40% CAGR).
Claritas Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Claritas Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CLAZF by Market Capitalization
Companies near Claritas Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Claritas Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Claritas Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Claritas Pharmaceuticals Inc's market cap moved from $106.10K to $ 3.66K, with a yearly change of -30.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.66K | 0.00% |
| 2024 | $3.66K | 0.00% |
| 2023 | $3.66K | -99.00% |
| 2022 | $365.86K | -93.39% |
| 2021 | $5.53 Million | +656.00% |
| 2020 | $731.72K | -97.31% |
| 2019 | $27.22 Million | -21.85% |
| 2018 | $34.83 Million | -87.22% |
| 2017 | $272.49 Million | +26.20% |
| 2016 | $215.92 Million | +203410.34% |
| 2015 | $106.10K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Claritas Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.66K USD |
| MoneyControl | $3.66K USD |
| MarketWatch | $3.66K USD |
| marketcap.company | $3.66K USD |
| Reuters | $3.66K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.